Experimental Drug Increased Regulatory T Cells in Trial
A new selective IL-2 agonist showed early potential for treating atopic dermatitis in a recent study of healthy volunteers.
Updated on Sept. 30, 2026 in Allergies
Live Poll
Is now a good time to pursue more aggressive medical treatments for chronic skin conditions?
Egle Therapeutics reported that its experimental drug, EGL-003, successfully boosted regulatory T cell counts in a small group of healthy participants. The findings, presented at the 35th EADV Congress in Vienna, lay the groundwork for upcoming clinical trials in patients with atopic dermatitis.
Why it matters
This development represents a new potential approach for managing atopic dermatitis, a condition affecting an estimated 21.2 million people in the U.S. and EU. By specifically targeting immune regulation, researchers hope to provide a more precise treatment option for those suffering from the chronic skin condition.
In a Phase 1 study of 24 healthy volunteers, researchers tested four single ascending doses of the selective IL-2 agonist EGL-003. Preliminary results showed a dose-dependent expansion of regulatory T cells without affecting other common immune cell populations.
The players
Egle Therapeutics
A Paris-based biotechnology company focused on the development of selective IL-2 therapies for immune-related diseases.
The details
EGL-003 works as a selective IL-2 agonist, a compound designed to stimulate the expansion of regulatory T cells. By increasing these specific immune cells, the treatment aims to calm the overactive immune response characteristic of atopic dermatitis. Observations from the study also suggested that the drug may encourage these cells to migrate to the skin, which is the primary site of inflammation in the condition.
Timeline
September 30, 2026: Phase 1 results were presented at the 35th EADV Congress.
October 1, 2026: Egle Therapeutics hosted an investor and analyst webcast.
Q4 2026: The company plans to start a multiple ascending dose study.
Q2 2027: Preliminary efficacy data from the follow-up study are targeted for release.
Q4 2027: Completion of the full study assessment is targeted.
Health Landscape
The study marks a specific entry into the competitive field of selective IL-2 agonists being explored to address autoimmune and inflammatory disorders. It moves these treatments beyond foundational research toward targeted clinical proof-of-concept for chronic skin conditions.
While these results are early and based on healthy volunteers, they highlight a developing area of interest for managing atopic dermatitis. Patients should continue working with their dermatologists on current standard treatments and discuss whether a clinical trial might be appropriate as new phases launch.
The takeaway
This preliminary study suggests that EGL-003 effectively expands immune-regulating cells without triggering broader, unwanted immune activation. For those living with atopic dermatitis, keeping track of emerging clinical trial milestones can provide insight into future treatment options.
Further reading
You can find more coverage on emerging research and condition management in our section on Allergies.
Live Poll
Is now a good time to pursue more aggressive medical treatments for chronic skin conditions?
